inflammatory bowel disease, psoriasis or Reiter’s syndrome) were studied. (Mean (SD) age at onset: 23-3 years (7-46) and mean (SD) disease duration: 23-0 years (12-78). Five (4 female, 1 male) had peripheral joint disease.

Interleukin-6 concentrations were compared with a modified Disease Activity Index (DAI),1 early morning stiffness (EMS), current age, age at onset, disease duration and the APRs. To determine IL-6 concentrations, anti-coagulated venous blood samples from 50 patients were collected at a tertiary referral centre and centrifuged immediately at 1000 x g for 10 minutes. The plasma was subsequently stored at -20°C until used for the assay. The ‘IL-6 IRMA’ (immunoradiometric assay) kit was used for determining IL-6 concentrations. (Control values <6 pg/ml, supplied by Medgenix Diagnostics, Brussels, Belgium).

PV (normal 1-50-1-72 mPAS) and ESR (Westergren; normal <15 mm/hour) were determined. Serum CRP levels by enzyme-linked immunoo-absorbtive assay (normal <0-01 g/l). Statistical assessments were carried out using Chi-squared or Pearson product-moment correlations.

Forty-three of 50 patients (86%) had IL-6 concentrations >6 pg/ml. This involved 84% of the males, all females and all patients with peripheral joint involvement; whereas the number with abnormal ESR, PV and CRP results were 57, 44, 40% respectively (figure). As shown, the mean and 1 SD figures are only above the normal cut off point for IL-6.

When the DAI of 43 patients was analysed it was found that six had low, 28 moderate and nine high disease activity (DAI: <14= low, 14-23= moderate, 24-32= high). The mean IL-6 values for each group were 13-2, 16-0 and 17-6 respectively. Correlates of the DAI with IL-6, the APRs, age (current and at onset) and duration of disease were all non significant.

Correlations between IL-6 and the APRs, age (current and at onset) plus disease and morning stiffness duration were all non significant. EMS correlated with ESR only (p < 0-02).

One patient developed uretis while being treated as an inpatient. The levels of IL-6 did not alter significantly before or after the flare up (51-7 and 43-9 pg/ml respectively). There were no clinical correlates found for those with high levels of IL-6 compared with those with low levels.

Increased serum concentrations of IL-6 have been described in patients with inflammatory disorders such as RA, Crohn’s disease2 and other conditions including major surgery,3 severe burns4 and bacterial infections.5 IL-6 is said to be the major cytokine responsible for APF production by the liver.6

Our data revealed that circulating concentrations of IL-6 were increased in the majority (86%) of patients with AS. By contrast abnormal values of ESR, PV and CRP were found in only 57, 44 and 40% respectively. Clearly, IL-6 is a more sensitive ‘marker’ for AS than the APRs. However, there was no correlation between IL-6 and any of the clinical variables. There was no relationship between IL-6 and the APRs.

This was a cross-sectional study to assess the levels of IL-6 in patients with AS with reference to a previously defined ‘normal’ level in an unmatched control population. As this study has not produced any biological explanation for the results further studies are required. It would be useful to know how IL-6 varies over time, with treatment and during flares in the disease.

There appears to be at least one laboratory variable that is raised in the clear majority of patients with AS in contrast to ESR, PV or CRP.

We thank the Arthritis and Rheumatism Council for Great Britain, the National Arkylosing Spondylitis Society, the Coats Trust and the Pontfient Trust for financial support; also Jean Wright and Trish Myers for their secretarial assistance.

Z. N. TUTUNCU A. BILGIE I. G. KENNEDY A. CALIN
Royal National Hospital for Rheumatic Diseases, Bath

Correspondence to Dr Andrei Calin, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1LW, United Kingdom


**HLA antigens in Japanese patients with high titre anti-ribonucleoprotein antibodies**

Antibodies to nuclear ribonucleoprotein (rNRP) have been proposed as characteristic of a distinct autoimmune disease, mixed connective tissue disease (MCTD).1 Previous reports have shown some correlations between genetic factors and MCTD in white groups.2 However, studies on HLA antigens in Japanese patients with MCTD remain controversial.3,4 We studied 36 Japanese patients who had anti-rNRP antibodies at high titres to find an association between HLA antigens and autoantibody production.

Thirty-six unrelated Japanese patients who had anti-rNRP antibodies at high titres (21:10240) were studied. All were women and their mean (SD) age was 37-9 (11-8) years. Thirty-two patients fulfilled the criteria for systemic lupus erythematosus (SLE)5 and the other four were diagnosed as having MCTD according to the disease criteria by Kasukawa et al.6 Twenty four patients had anti-Sm antibodies and twelve did not. All had been suffering from Raynaud’s phenomenon. The patients were divided into two groups, one with anti-Sm antibodies (group A, n = 24) and the other without anti-Sm (group B, n = 12). The mean age, the median duration of disease and the titre of anti-rNRP were not statistically different between the two groups (data not shown). Titres of anti-rNRP and anti-Sm antibodies were detected by passive haemagglutin test. HLA-A, B, C and DR typing was performed by using standard lymphocytoxicity method. Chi-square method was used for statistical analysis and the p value was corrected for the number of antigens tested (pc < 0-05).

Frequencies of HLA-A, B, C and DR antigens in 36 patients and 105 healthy controls are shown in the table. There were no apparent differences between the patient group and healthy controls. Although there were no significant differences between group A and controls, a strong association with DR9 was observed in group B compared with normal controls (83-3% vs 32-7%, pc < 0-05).

<table>
<thead>
<tr>
<th></th>
<th>HLA-DR9 (17)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(105)</td>
<td>(36)</td>
<td></td>
</tr>
</tbody>
</table>

**Anti-Sm antibodies in patients with or without HLA-DR9.**
Next we evaluated the titres of anti-Sm antibodies between DR9 positive and negative patients. As shown in the figure, the mean titre of anti-Sm antibodies was higher in patients with DR9 (1:136 v. 1:1741, p < 0.02) while titres of anti-nRNP were not significantly different between DR9 positive and negative groups (data not shown).

Antibodies to nRNP are frequently detected in sera from patients with MCTD as well as SLE, and at a low frequency, from other autoimmune disorders. Patients who have high titre anti-nRNP but not anti-Sm antibodies share some clinical signs, including Raynaud’s phenomenon and swollen hands. They have overlapping features of SLE, polymyositis and scleroderma. The disease criteria for MCTD, however, has now been under discussion. Previous reports have shown some correlations between MCTD and DR4 in white groups. Genth et al found that DR4 was more frequent in patients with anti-nRNP antibodies than healthy controls. In Japanese, however, studies on HLA antigens in patients with MCTD revealed conflicting results.

We selected patients who had high titre anti-nRNP antibodies. There were only four individuals who shared features of SLE, polymyositis, and scleroderma. Our aim was not to find an association between genetic factors and SLE or MCTD, but to clarify the pathogenesis involved in production of autoantibodies. In our 36 patients, although there was no association between the presence of certain class I or II antigens with either anti-nRNP or Sm antibody production, there was a negative correlation between DR9 and anti-Sm antibodies. These results suggest that HLA-DR9 or a closely linked gene may predispose to the production of anti-nRNP and anti-Sm antibodies. Since the number of patients studied remains small, further studies will be needed to confirm our observation.

Rice bodies in the pleural aspirate of a patient with rheumatoid arthritis

Rice bodies (RB), aggregations of fibrin and cells so named because they resemble polished white rice, are common findings in the synovial fluid of rheumatoid arthritis (RA). Microscopically, RB vary in shape and size, some being so large as to preclude effective removal by routine needle aspiration. However, RB can occur at any time during the course of RA and are not related to the severity of clinical or radiological change, but removal of RB from a joint is accompanied by clinical improvement and reduction of synovitis. RB have not previously been reported in other body fluids.

A woman of 56 who had suffered RA for 11 years presented with active systemic disease and serositis. Examination revealed a left sided pleural effusion, ulcerated rheumatoid nodules over both elbows and a moderate synovitis of both knees. Other joints showed only chronic deformity. Investigations showed hypochromic microcytic anaemia (Hb:8.3 g/dl, MCV:70 fl, MCH:19.7 pg), thrombocytosis (PLT:637 x 10^9/L), an acute phase response (CRP:79 mg/L, PV:1-93 mPa) and evidence of circulating immune complexes (CIC) and complement consumption (RfH:2000 IU/ml, C4<0.1 g/L, CH50<30 units, C1q--binding>80 units). A careful history did not reveal any other reason for this patient’s anaemia. Investigations including upper and lower endoscopy were all normal. One month later her Hb had improved (Hb:9.6 g/dl, MCV:82 fl, MCH:23 pg) in parallel with her disease activity.

Plural and synovial fluids were each aspirated using the same size needle, that is, green (21 g) which is routinely used for these procedures in our practice. The figure shows copious RB present in the plural fluid aspirate only (picture taken immediately after aspiration). Mycobacterial culture and a Mantoux test were negative. Biochemical analysis of the pleural aspirate revealed an exudate (protein 35 g/l and a RhF of 1:160).
HLA antigens in Japanese patients with high titre anti-ribonucleoprotein antibodies.

T Kawai, K Tani, T Okubo, H Suzuki, A Okamura, M Minami and K Katoh

doi: 10.1136/ard.53.6.426

Updated information and services can be found at:
http://ard.bmj.com/content/53/6/426.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes